{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:09:36Z","timestamp":1792462176961,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.clinthera.2006.08.014","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T15:16:16Z","timestamp":1158678976000},"page":"1123-1132","source":"Crossref","is-referenced-by-count":27,"title":["Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case\/noncase analysis of spontaneous reports"],"prefix":"10.1016","volume":"28","author":[{"given":"David","family":"Sanchez-Matienzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Castellsague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Perez-Gutthann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.08.014_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archinte.154.3.311","article-title":"Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors","volume":"154","author":"Garcia Rodriguez","year":"1994","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2006.08.014_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/j.1875-9114.1997.tb03747.x","article-title":"A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom","volume":"17","author":"Garcia Rodriguez","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2006.08.014_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.305.6858.865","article-title":"The role of non-steroidal anti-inflammatory drugs in acute liver injury","volume":"305","author":"Garcia Rodriguez","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.08.014_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/lt.500050607","article-title":"Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation","volume":"5","author":"Fontana","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.clinthera.2006.08.014_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1572-0241.1999.01093.x","article-title":"Severe hepatotoxicity associated with bromfenac sodium","volume":"94","author":"Moses","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2006.08.014_bib6","first-page":"596","article-title":"Hepatotoxicity associated with nimesulide: Data from the Spanish Pharmacovigilance System","volume":"72","author":"Macia","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.014_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002280100312","article-title":"Fatal hepatotoxicity secondary to nimesulide","volume":"57","author":"Merlani","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.014_bib8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00002018-200225090-00003","article-title":"Mechanisms of NSAID-induced hepatotoxicity: Focus on nimesulide","volume":"25","author":"Boelsterli","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.327.7405.18","article-title":"Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal anti-inflammatory drugs","volume":"327","author":"Traversa","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.08.014_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0016-5085(93)90428-F","article-title":"Sulindac-associated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration","volume":"104","author":"Tarazi","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2006.08.014_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00001648-199311000-00004","article-title":"The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs","volume":"4","author":"Perez Gutthann","year":"1993","journal-title":"Epidemiology"},{"key":"10.1016\/j.clinthera.2006.08.014_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2165\/00002018-199615010-00005","article-title":"Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention","volume":"15","author":"Manoukian","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00045391-200007030-00003","article-title":"The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib","volume":"7","author":"Maddrey","year":"2000","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2006.08.014_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74867-4","article-title":"COX 2 inhibitor and fulminant hepatic failure","volume":"353","author":"McCormick","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.08.014_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7326\/0003-4819-137-1-200207020-00030","article-title":"Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis","volume":"137","author":"Alegria","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2006.08.014_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.dld.2003.09.006","article-title":"A rare case of rofecoxib-induced cholestatic hepatitis","volume":"35","author":"Harsch","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinthera.2006.08.014_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0168-8278(02)00177-0","article-title":"Rofecoxib-induced cholestatic hepatitis: Treatment with molecular adsorbent recycling system (MARS)","volume":"37","author":"Huster","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2006.08.014_bib18","first-page":"S2","article-title":"Effect of control of confounding in the estimation of the Proportional Reporting Ratio","volume":"13","author":"Sanchez-Matienzo","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib19","first-page":"S324","article-title":"Choosing the measure of relative proportional reporting in quantitative analyses of spontaneous reports","volume":"13","author":"Arana","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigi lance: Three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/pds.581","article-title":"Association between terbinafine and arthralgia, fever and urticaria: Symptoms or syndrome?","volume":"10","author":"van Puijenbroek","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib22","first-page":"521","article-title":"The association between antidepressant use and hypoglycemia and hyperglycemia","volume":"13","author":"Derijks","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib23","series-title":"Spontaneous reporting system","year":"2006"},{"key":"10.1016\/j.clinthera.2006.08.014_bib26","series-title":"Guidance for Industry E2B(M): Data Elements for Transmission of Individual Case Safety Reports","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.014_bib27","series-title":"International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"2003"},{"key":"10.1016\/j.clinthera.2006.08.014_bib30","series-title":"Adverse Reaction Terminology","year":"2001"},{"key":"10.1016\/j.clinthera.2006.08.014_bib31","series-title":"Development and Rational Use of Standardised MedDRA Queries (SMQs): Retrieving Adverse Drug Reactions with MedDRA","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.014_bib32","series-title":"Drug-Induced Hepatic Injury","author":"Stricker","year":"1992"},{"key":"10.1016\/j.clinthera.2006.08.014_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 3A","key":"10.1016\/j.clinthera.2006.08.014_bib34","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/S0002-9343(00)00682-3","article-title":"Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs","volume":"110","author":"Hernandez-Diaz","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2006.08.014_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug-induced liver injury: A population based casecontrol study","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.014_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2001.20645","article-title":"Comparison of two clinical scales for causality assessment in hepatotoxicity","volume":"33","author":"Lucena","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2006.08.014_bib37","series-title":"PhRMA\/FDA\/AASLD Drug-induced hepatotoxicity white paper postmarketing considerations","year":"2000"},{"key":"10.1016\/j.clinthera.2006.08.014_bib38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/bmj.319.7224.1541","article-title":"Accuracy of hepatic adverse drug reaction reporting in one English health region","volume":"319","author":"Aithal","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.08.014_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: A French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2006.08.014_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pds.995","article-title":"Disproportionality analyses of spontaneous reports","volume":"13","author":"Hennessy","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/pds.1002","article-title":"The reporting odds ratio versus the proportional reporting ratio: \u2018Deuce\u2019","volume":"13","author":"Waller","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pds.994","article-title":"Assessments of disproportionality","volume":"13","author":"Mann","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2006.08.014_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: Lessons learned from the bromfenac experience","volume":"15","author":"Goldkind","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T15:02:33Z","timestamp":1707231753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0149291806001949"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.08.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}